▲ +146.70% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Trillium Therapeutics in the last 3 months. The average price target is $21.83, with a high forecast of $28.00 and a low forecast of $14.00. The average price target represents a 146.70% upside from the last price of $8.85.
The current consensus among 7 investment analysts is to buy stock in Trillium Therapeutics. This Buy consensus rating has held steady for over two years.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.